戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 istar Furth recipients with a single dose of antilymphocyte serum 5 days before bone marrow transplan
2 chieved when recipients were pretreated with antilymphocyte serum alone or antilymphocyte serum plus
3                      Various groups received antilymphocyte serum (ALS) (days -1, 0, and +2), rapamyc
4           This study assessed the ability of antilymphocyte serum (ALS) and cyclosporine A (CsA) to i
5          Group 2 was treated with short-term antilymphocyte serum (ALS) and cyclosporine-A (CsA).
6             Perigraft immunosuppression with antilymphocyte serum (ALS) and postgraft infusion of don
7  bone marrow (BM) into mice conditioned with antilymphocyte serum (ALS) and sirolimus (Sir) prolongs
8  bone marrow (DSBM) to mice conditioned with antilymphocyte serum (ALS) and sirolimus can result in s
9  immunosuppression by initial treatment with antilymphocyte serum (ALS) followed by coadministration
10 ne marrow (BM) infusion in mice treated with antilymphocyte serum (ALS) induces specific unresponsive
11 00 microg) of u-5 or u-7 each with 0.5 ml of antilymphocyte serum (ALS) on day -7 led to 60% and 100%
12 nditioned with total body irradiation and or antilymphocyte serum (ALS) on the incidence of GVHD and
13 reptavidin treatment combined with 0.5 ml of antilymphocyte serum (ALS) transient immunosuppression l
14 ptive transfer of iMDCs combined with 0.5 mL antilymphocyte serum (ALS) transient immunosuppression o
15 of rejection by BLI can aid in the timing of antilymphocyte serum (ALS) treatment for prolonging isle
16        B10 (H-2b) mice were conditioned with antilymphocyte serum (ALS), 100 cGy total body irradiati
17 vestigated the effect of T cell depletion by antilymphocyte serum (ALS), a polyclonal anti-T cell Ab,
18 th tolerance in mice treated with sirolimus, antilymphocyte serum (ALS), and donor-specific bone marr
19 dies described, administration of polyclonal antilymphocyte serum (ALS), donor-specific bone marrow (
20                      A regimen consisting of antilymphocyte serum (ALS), sirolimus, and donor bone-ma
21 er leukocytes contained in the unmodified or antilymphocyte serum (ALS)-depleted BN intestine at the
22 -activated host T cells combined with 0.5 ml antilymphocyte serum (ALS)-transient immunosuppression o
23 cell responses after limb transplantation in antilymphocyte serum (ALS)-treated recipients given a sh
24  induced by donor bone marrow cells (BMC) in antilymphocyte serum (ALS)-treated recipients.
25 recipients transiently immunosuppressed with antilymphocyte serum (ALS).
26 one (BM), or bone marrow in conjunction with antilymphocyte serum (ALS).
27 ugmenting the unresponsiveness induced by an antilymphocyte serum (ALS)/donor-specific bone marrow (B
28 penhagen Irish bone marrow cells followed by antilymphocyte serum and FK-506.
29   NOD or NOD.NON mice were treated with ALS (antilymphocyte serum) and transplanted with NOR islets +
30 elated with the total steroid dosage, use of antilymphocyte serum, and number of rejection episodes.
31  using the terms "monoclonal antibodies" or "antilymphocyte serum," and "kidney transplantation," "hu
32 vely induces tolerance to skin allografts in antilymphocyte serum- and rapamycin-treated recipients i
33  per day (daily) from day 0 through day +10, antilymphocyte serum at 10 mg at day +10 (single dose),
34                                              Antilymphocyte serum can reverse overt type 1 diabetes i
35 r than CCL18-dependent, since treatment with antilymphocyte serum completely abrogated the CCL18-indu
36  11-day course of tacrolimus and one dose of antilymphocyte serum (day 10).
37  was induced by intraperitoneal injection of antilymphocyte serum, followed by intrathymic inoculatio
38 he thymus, with a single concomitant dose of antilymphocyte serum, has been demonstrated in rodents,
39 permanent graft acceptance among transiently antilymphocyte serum-immunosuppressed TMX recipients wit
40  of cardiac allografts to 70% of transiently antilymphocyte serum-immunosuppressed TMX recipients.
41                                     Although antilymphocyte serum immunosuppression significantly red
42 portal vein with one injection (1 ml) of rat antilymphocyte serum intraperitoneally.
43  A and mycophenolate mofetil (12 doses), and antilymphocyte serum (one dose); and transplanted with T
44                    Depletion of T cells with antilymphocyte serum or pharmacological inhibition of MM
45 retreated with antilymphocyte serum alone or antilymphocyte serum plus anti-NK monoclonal antibodies.
46                                    A form of antilymphocyte serum, rabbit anti-mouse thymocyte globul
47  for induction of allograft tolerance by the antilymphocyte serum/rapamycin/donor BMC-infusion protoc
48 ng regimen based on recipient treatment with antilymphocyte serum, tacrolimus, and low-dose total-bod
49  T cells induces permanent graft survival in antilymphocyte serum transiently immunosuppressed syngen
50  (P<0.05) that was prolonged to 25 days with antilymphocyte serum treatment.
51 additional effectiveness in combination with antilymphocyte serum with or without donor-specific bone